BridgeBio Pharma, Inc. Investment Income, Interest
BridgeBio Pharma, Inc. (BBIO) reported Investment Income, Interest of $6.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-10
- BridgeBio Pharma, Inc. investment income, interest for the quarter ending 2026-06-30 was $6.66M, a 70.83% increase year-over-year.
- BridgeBio Pharma, Inc. investment income, interest for the quarter ending 2026-03-31 was $6.25M, a 15.99% increase year-over-year.
- BridgeBio Pharma, Inc. investment income, interest for the quarter ending 2025-12-31 was $4.33M, a 7.50% decline year-over-year.
- BridgeBio Pharma, Inc. investment income, interest for the quarter ending 2025-09-30 was $6.24M, a 89.29% increase year-over-year.
- BridgeBio Pharma, Inc. investment income, interest for fiscal 2025 was $19.85M, a 15.10% increase from fiscal 2024.
- BridgeBio Pharma, Inc. investment income, interest for fiscal 2024 was $17.25M, a 4.37% decline from fiscal 2023.
- BridgeBio Pharma, Inc. investment income, interest for fiscal 2023 was $18.04M, a 139.17% increase from fiscal 2022.
- BridgeBio Pharma, Inc. investment income, interest for fiscal 2022 was $7.54M, a 565.67% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.66M 10-Q · filed 2026-08-10 | $12.90M 10-Q · filed 2026-08-10 | $17.24M derived: sum of 3 quarters · filed 2026-08-10 | $23.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $6.25M 10-Q · filed 2026-05-07 | $10.58M derived: sum of 2 quarters · filed 2026-05-07 | $16.82M derived: sum of 3 quarters · filed 2026-05-07 | $20.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.57M derived: sum of 2 quarters · filed 2026-02-24 | $14.47M derived: sum of 3 quarters · filed 2026-08-10 | $19.85M 10-K · filed 2026-02-24 |
| 2025-09-30 | $6.24M 10-Q · filed 2025-10-29 | $10.14M derived: sum of 2 quarters · filed 2026-08-10 | $15.52M 10-Q · filed 2025-10-29 | $20.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.90M 10-Q · filed 2026-08-10 | $9.28M 10-Q · filed 2026-08-10 | $13.97M derived: sum of 3 quarters · filed 2026-08-10 | $17.26M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $5.38M 10-Q · filed 2026-05-07 | $10.07M derived: sum of 2 quarters · filed 2026-05-07 | $13.36M derived: sum of 3 quarters · filed 2026-05-07 | $18.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.98M derived: sum of 2 quarters · filed 2026-02-24 | $13.17M derived: sum of 3 quarters · filed 2026-02-24 | $17.25M 10-K · filed 2026-02-24 |
| 2024-09-30 | $3.30M 10-Q · filed 2025-10-29 | $8.49M derived: sum of 2 quarters · filed 2025-10-29 | $12.57M 10-Q · filed 2025-10-29 | $18.14M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $5.20M 10-Q · filed 2025-08-05 | $9.27M 10-Q · filed 2025-08-05 | $14.85M derived: sum of 3 quarters · filed 2026-02-24 | $18.64M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $4.08M 10-Q · filed 2025-04-29 | $9.65M derived: sum of 2 quarters · filed 2026-02-24 | $13.45M derived: sum of 3 quarters · filed 2026-02-24 | $17.96M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $9.37M derived: sum of 2 quarters · filed 2026-02-24 | $13.88M derived: sum of 3 quarters · filed 2026-02-24 | $18.04M 10-K · filed 2026-02-24 |
| 2023-09-30 | $3.79M 10-Q · filed 2024-11-12 | $8.31M derived: sum of 2 quarters · filed 2024-11-12 | $12.46M 10-Q · filed 2024-11-12 | $16.55M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $4.51M 10-Q · filed 2024-08-01 | $8.67M 10-Q · filed 2024-08-01 | $12.76M derived: sum of 3 quarters · filed 2025-02-20 | $15.18M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $4.15M 10-Q · filed 2024-05-02 | $8.24M derived: sum of 2 quarters · filed 2025-02-20 | $10.66M derived: sum of 3 quarters · filed 2025-02-20 | $11.43M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $6.51M derived: sum of 2 quarters · filed 2025-02-20 | $7.28M derived: sum of 3 quarters · filed 2025-02-20 | $7.54M 10-K · filed 2025-02-20 |
| 2022-09-30 | $2.42M 10-Q · filed 2023-11-02 | $3.18M derived: sum of 2 quarters · filed 2023-11-02 | $3.45M 10-Q · filed 2023-11-02 | $3.63M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $766.00K 10-Q · filed 2023-08-03 | $1.03M 10-Q · filed 2023-08-03 | $1.22M derived: sum of 3 quarters · filed 2024-02-22 | $1.45M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $267.00K 10-Q · filed 2023-05-04 | $449.00K derived: sum of 2 quarters · filed 2024-02-22 | $683.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.01M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $416.00K derived: sum of 2 quarters · filed 2024-02-22 | $739.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.13M 10-K · filed 2024-02-22 |
| 2021-09-30 | $234.00K 10-Q · filed 2022-11-03 | $557.00K derived: sum of 2 quarters · filed 2022-11-03 | $951.00K 10-Q · filed 2022-11-03 | $1.40M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $323.00K 10-Q · filed 2022-08-04 | $717.00K 10-Q · filed 2022-08-04 | $1.17M derived: sum of 3 quarters · filed 2023-02-23 | $1.86M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $394.00K 10-Q · filed 2022-05-05 | $842.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.53M derived: sum of 3 quarters · filed 2023-02-23 | $2.47M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.14M derived: sum of 2 quarters · filed 2023-02-23 | $2.07M derived: sum of 3 quarters · filed 2023-02-23 | $4.01M 10-K · filed 2023-02-23 |
| 2020-09-30 | $692.00K 10-Q · filed 2021-11-04 | $1.63M derived: sum of 2 quarters · filed 2021-11-04 | $3.57M 10-Q · filed 2021-11-04 | $5.98M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $934.00K 10-Q · filed 2021-08-05 | $2.88M 10-Q · filed 2021-08-05 | $5.29M derived: sum of 3 quarters · filed 2022-02-25 | $8.02M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $1.94M 10-Q · filed 2021-05-06 | $4.35M derived: sum of 2 quarters · filed 2022-02-25 | $7.09M derived: sum of 3 quarters · filed 2022-02-25 | $8.75M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $5.15M derived: sum of 2 quarters · filed 2022-02-25 | $6.81M derived: sum of 3 quarters · filed 2022-02-25 | $8.91M 10-K · filed 2022-02-25 |
| 2019-09-30 | $2.74M 10-Q · filed 2020-11-05 | $4.40M derived: sum of 2 quarters · filed 2020-11-05 | $6.50M 10-Q · filed 2020-11-05 | $7.98M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.66M 10-Q · filed 2020-08-11 | $3.77M 10-Q · filed 2020-08-11 | $5.24M derived: sum of 3 quarters · filed 2021-02-25 | $5.77M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $2.11M 10-Q · filed 2020-05-14 | $3.58M derived: sum of 2 quarters · filed 2021-02-25 | $4.11M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.00M derived: sum of 2 quarters · filed 2021-02-25 | $2.00M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $528.00K 10-Q · filed 2019-11-08 | $531.00K 10-Q · filed 2019-11-08 | ||
| 2017-12-31 | $39.00K 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |